MAPK1 and cancer: ERK2 is known to modulate PD-L1 expression and its inhibition has been shown to improve anti-PD-L1 blockade in several cancer types, including NSCLC (Ng et al., 2018; Kumar et al., 2020; Henry et al., 2021; Luo et al., 2021).